These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21458597)

  • 1. Continuous safety monitoring for randomized controlled clinical trials.
    Piller LB; Silverman MH; Ball G
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S1. PubMed ID: 21458597
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 1: Ethical considerations.
    Ball G; Piller LB; Silverman MH
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S2-4. PubMed ID: 21664987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discussion of paper by Korn and Freidlin.
    Wittes J
    Am J Bioeth; 2011 Mar; 11(3):13-4. PubMed ID: 21400376
    [No Abstract]   [Full Text] [Related]  

  • 4. Interim analysis in randomized trials: DAMOCLES' sword?
    Besselink MG; van der Graaf Y; Gooszen HG
    J Clin Epidemiol; 2010 Apr; 63(4):353-4. PubMed ID: 19959333
    [No Abstract]   [Full Text] [Related]  

  • 5. The many moral responsibilities of independent data-monitoring committees.
    Braillon A
    Am J Bioeth; 2011 Mar; 11(3):16-7. PubMed ID: 21400378
    [No Abstract]   [Full Text] [Related]  

  • 6. Early stopping rules in oncology: considerations for clinicians.
    Mukherjee SD; Goffin JR; Taylor V; Anderson KK; Pond GR
    Eur J Cancer; 2011 Nov; 47(16):2381-6. PubMed ID: 21684153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Data monitoring committees and stopping trials-Giving participants a voice.
    Trachtman H; Caplan A
    Contemp Clin Trials; 2018 May; 68():146. PubMed ID: 29567282
    [No Abstract]   [Full Text] [Related]  

  • 9. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 3: Design considerations.
    Ball G; Silverman MH
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S8-10. PubMed ID: 21664988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data monitoring (and safety) committees--what are they and why do we need them? Primary Care Alliance for Clinical Trials (PACT) Network.
    Pirotta M; Chondros P;
    Aust Fam Physician; 2004 Nov; 33(11):950-1, 956. PubMed ID: 15584339
    [No Abstract]   [Full Text] [Related]  

  • 11. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 12. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.
    Wittes J; Barrett-Connor E; Braunwald E; Chesney M; Cohen HJ; Demets D; Dunn L; Dwyer J; Heaney RP; Vogel V; Walters L; Yusuf S
    Clin Trials; 2007; 4(3):218-34. PubMed ID: 17715247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Data monitoring and safety committees and their operations.
    Rouse DJ
    Obstet Gynecol Surv; 2003 May; 58(5):329-36. PubMed ID: 12719675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
    Anderson JR; Krailo M
    Am J Bioeth; 2011 Mar; 11(3):18-9. PubMed ID: 21400379
    [No Abstract]   [Full Text] [Related]  

  • 15. The statistician and the data monitoring committee.
    D'Agostino RB
    Stat Med; 2004 May; 23(10):1501-2. PubMed ID: 15122726
    [No Abstract]   [Full Text] [Related]  

  • 16. Problems of stopping trials early.
    Guyatt GH; Briel M; Glasziou P; Bassler D; Montori VM
    BMJ; 2012 Jun; 344():e3863. PubMed ID: 22705814
    [No Abstract]   [Full Text] [Related]  

  • 17. Ethical issues arising when interim data in clinical trials is restricted to independent data monitoring committees.
    Wells RJ; Gartside PS; McHenry CL
    IRB; 2000 Jan; 22(1):7-11. PubMed ID: 12546010
    [No Abstract]   [Full Text] [Related]  

  • 18. The dilemma of data-safety monitoring: provision of significant new data to research participants.
    Peppercorn J; Buss WG; Fost N; Godley PA
    Lancet; 2008 Feb; 371(9611):527-9. PubMed ID: 18262043
    [No Abstract]   [Full Text] [Related]  

  • 19. [Monitoring the safety of participants in randomised clinical trials: basis and methods].
    Tijssen JG
    Ned Tijdschr Geneeskd; 2008 Mar; 152(12):674-8. PubMed ID: 18438062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early viewing of noninferiority trials in progress.
    Dignam JJ
    J Clin Oncol; 2005 Aug; 23(24):5461-3. PubMed ID: 16027438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.